Logo image of ONVO

ORGANOVO HOLDINGS INC (ONVO) Stock Price, Quote, News and Overview

NASDAQ:ONVO - Nasdaq - US68620A2033 - Common Stock - Currency: USD

1.72  +0.06 (+3.61%)

After market: 1.69 -0.03 (-1.74%)

ONVO Quote, Performance and Key Statistics

ORGANOVO HOLDINGS INC

NASDAQ:ONVO (4/17/2025, 8:00:02 PM)

After market: 1.69 -0.03 (-1.74%)

1.72

+0.06 (+3.61%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High21.96
52 Week Low1.56
Market Cap2.92M
Shares1.70M
Float1.68M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO08-02 2013-08-02


ONVO short term performance overview.The bars show the price performance of ONVO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

ONVO long term performance overview.The bars show the price performance of ONVO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ONVO is 1.72 USD. In the past month the price decreased by -53.19%. In the past year, price decreased by -86.97%.

ORGANOVO HOLDINGS INC / ONVO Daily stock chart

ONVO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.09 306.02B
AMGN AMGEN INC 13.99 149.08B
GILD GILEAD SCIENCES INC 22.68 130.32B
VRTX VERTEX PHARMACEUTICALS INC 1686.55 125.74B
REGN REGENERON PHARMACEUTICALS 12.34 61.56B
ARGX ARGENX SE - ADR 318.82 36.23B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 30.51B
ONC BEIGENE LTD-ADR N/A 24.88B
BNTX BIONTECH SE-ADR N/A 23.74B
NTRA NATERA INC N/A 20.02B
SMMT SUMMIT THERAPEUTICS INC N/A 18.15B
BIIB BIOGEN INC 7.2 17.36B

About ONVO

Company Profile

ONVO logo image Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2013-08-02. The firm is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). The company is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. The company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.

Company Info

ORGANOVO HOLDINGS INC

Suite 100, 11555 Sorrento Valley Road

San Diego CALIFORNIA 92075 US

CEO: Keith Murphy

Employees: 20

Company Website: https://organovo.com/

Investor Relations: http://ir.organovo.com/phoenix.zhtml?c=254194&p=irol-irhome

Phone: 18582241000

ORGANOVO HOLDINGS INC / ONVO FAQ

What is the stock price of ORGANOVO HOLDINGS INC today?

The current stock price of ONVO is 1.72 USD. The price increased by 3.61% in the last trading session.


What is the ticker symbol for ORGANOVO HOLDINGS INC stock?

The exchange symbol of ORGANOVO HOLDINGS INC is ONVO and it is listed on the Nasdaq exchange.


On which exchange is ONVO stock listed?

ONVO stock is listed on the Nasdaq exchange.


What is ORGANOVO HOLDINGS INC worth?

ORGANOVO HOLDINGS INC (ONVO) has a market capitalization of 2.92M USD. This makes ONVO a Nano Cap stock.


How many employees does ORGANOVO HOLDINGS INC have?

ORGANOVO HOLDINGS INC (ONVO) currently has 20 employees.


Is ORGANOVO HOLDINGS INC (ONVO) expected to grow?

The Revenue of ORGANOVO HOLDINGS INC (ONVO) is expected to grow by 126.67% in the next year. Check the estimates tab for more information on the ONVO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ORGANOVO HOLDINGS INC (ONVO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ORGANOVO HOLDINGS INC (ONVO) stock pay dividends?

ONVO does not pay a dividend.


What is the Price/Earnings (PE) ratio of ORGANOVO HOLDINGS INC (ONVO)?

ORGANOVO HOLDINGS INC (ONVO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.49).


What is the Short Interest ratio of ORGANOVO HOLDINGS INC (ONVO) stock?

The outstanding short interest for ORGANOVO HOLDINGS INC (ONVO) is 8.04% of its float. Check the ownership tab for more information on the ONVO short interest.


ONVO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ONVO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ONVO. The financial health of ONVO is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ONVO Financial Highlights

Over the last trailing twelve months ONVO reported a non-GAAP Earnings per Share(EPS) of -4.49. The EPS increased by 60.26% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -322.19%
ROE -3402.47%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-473%
Sales Q2Q%380%
EPS 1Y (TTM)60.26%
Revenue 1Y (TTM)-50.2%

ONVO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 46% to ONVO. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of 96.31% and a revenue growth 126.67% for ONVO


Ownership
Inst Owners16.11%
Ins Owners1.23%
Short Float %8.04%
Short Ratio0.15
Analysts
Analysts45.71
Price TargetN/A
EPS Next Y96.31%
Revenue Next Year126.67%